This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Top Stock Reports for NVIDIA, Pfizer & Abbott
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including NVIDIA (NVDA), Pfizer (PFE) and Abbott Laboratories (ABT).
Moderna (MRNA) Inks Europe Supply Deal for COVID-19 Vaccine
by Zacks Equity Research
Moderna (MRNA) signs a deal to supply up to 160 million vaccine doses to European Commission The vaccine is under review in Europe.
UPS Soars 71.1% in the Past 6 Months: More Room for Rally?
by Zacks Equity Research
The surge in e-commerce demand in the current pandemic scenario bodes well for the UPS stock.
BP Jumps 38.3% Month To Date: What's Driving the Rally?
by Zacks Equity Research
Improving oil prices on encouraging coronavirus vaccine news aid BP plc (BP).
Wall Street Set to Close the Year Higher: 5 Top Growth Picks
by Zacks Equity Research
The stock market is poised to close the year positively, driven by a flurry of encouraging developments, making it a good time to invest in growth stocks like Beazer Homes (BZH) and Axcelis (ACLS).
Stock Market News for Nov 25, 2020
by Zacks Equity Research
The Dow crossed the 30,000 points mark on Tuesday as investors hoped for a swift economic recovery following progress in coronavirus vaccine development and transition of President-elect Joe Biden to the White House.
Dow Tops 30,000: 5 Stocks Driving the ETF
by Sweta Killa
The Dow Jones topped the 30,000 milestone for the first time on vaccine optimism, and improving prospects for the smooth transition of President-elect Joe Biden to White House.
Should Value Investors Pick Pfizer (PFE) Stock Right Now?
by Zacks Equity Research
Is Pfizer (PFE) a great pick from the value investor's perspective right now? Read on to know more.
Small-Cap ETF (DWAS) Hits New 52-Week High
by Sweta Killa
This small-cap ETF hits a new 52-week high. Are more gains in store for this ETF?
3 mREIT Stocks to Buy Amid Vaccine Hopes & Thanksgiving Cheer
by Devyani Chamria
The overall optimism in the market, thanks to the positive news on the vaccine front and strong rebound in the economy creates a favorable backdrop for mortgage REITs like AGNC, NLY, and RC.
Vaccine News Propels Market Higher: 5 Potential Gainers
by Zacks Equity Research
Promising vaccine news aided the market in moving higher with further economic recovery in sight, making it a good time to invest in fundamentally sound names like EnPro (NPO) and APi Group (APG).
Thanksgiving Brings Strong Seasonal Market Trends: 5 Picks
by Tirthankar Chakraborty
Traditionally, the stock market tends to perform well from the Thanksgiving week till the end of the year. This calls for investing in growth stocks like General Motors (GM) & Malibu Boats (MBUU).
Permian Producers in Focus as Crude Price Picks Up
by Nilanjan Banerjee
Improving oil prices are definitely a boon for Permian explorers like Devon (DVN), Diamondback (FANG), Concho (CXO) and Matador (MTDR).
Dow Hits 30K for First Time: 7 Stocks Driving the ETF Rally
by Sanghamitra Saha
Wall Street seemed super-excited as the Dow Jones reached 30,000 for the first time in history on Nov 24.
ETFs to Play as Vaccine News Looks to Outdo Virus Fear
by Sanghamitra Saha
After almost a year-long wait, the month of November started delivering sweet surprises to investors in the form of back-to-back vaccine news.
The Zacks Analyst Blog Highlights: Gilead, Eli Lilly, Incyte and Pfizer
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Gilead, Eli Lilly, Incyte and Pfizer
Spread of Top-Ranked Value ETFs to Bet on Vaccine Optimism
by Sweta Killa
The potential arrival of a coronavirus vaccine will end the pandemic crisis, keeping the economy recovery intact, and will boost consumer spending and in turn lift value stocks.
Pfizer (PFE) Begins Phase III Study on Hemophilia Candidate
by Zacks Equity Research
Pfizer (PFE) doses the first participant in the late-stage BASIS study, currently investigating marstacimab to address severe hemophilia A or B with or without inhibitors.
How Does AstraZeneca's COVID-19 Vaccine Data Compare to Others'?
by Kinjel Shah
Interim data from late-stage studies on AstraZeneca (AZN) COVID-19 vaccine shows that the candidate was, on an average, about 70% effective in preventing COVID-19.
5 ETFs That Gained in Double Digits Last Week
by Sweta Killa
Inside the ETFs that gained in double-digits last week.
Glaxo's (GSK) RSV Vaccine for Pregnant Women Enters Phase III
by Zacks Equity Research
Glaxo (GSK) is developing vaccine against respiratory syncytial virus for pediatric patients, pregnant women and older adults. The candidates hold significant potential.
3 Coronavirus Vaccine Makers Near Finish Line in November
by Zacks Equity Research
Positive developments related to coronavirus vaccine candidates have supported stock markets in November. Three leading coronavirus vaccine candidates achieve encouraging efficacy rate.
Celebrate Thanksgiving Week With These ETFs
by Sweta Killa
Thanksgiving week is here and history shows that this holiday-shortened week is a bullish feast for stock investors.
5 Top-Performing Leveraged ETF Areas of Last Week
by Sanghamitra Saha
Last week for Wall Street was all about vaccine optimism marred somewhat by rising virus cases and fears of further lockdowns.
Matador Resources (MTDR) Up 50.4% MTD: What's Driving It?
by Zacks Equity Research
Improving oil prices on encouraging coronavirus vaccine news aid Matador Resources (MTDR).